Alison Pilgrim
About
In The Last Decade
Alison Pilgrim
21 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 88
- Psychiatry and Mental health 807
- Pathology and Forensic Medicine 588
- Physiology 494
- Surgery 456
- Biomaterials 260
Countries citing papers authored by Alison Pilgrim
This map shows the geographic impact of Alison Pilgrim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison Pilgrim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison Pilgrim more than expected).
Fields of papers citing papers by Alison Pilgrim
This network shows the impact of papers produced by Alison Pilgrim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison Pilgrim. The network helps show where Alison Pilgrim may publish in the future.
Co-authorship network of co-authors of Alison Pilgrim
This figure shows the co-authorship network connecting the top 25 collaborators of Alison Pilgrim. A scholar is included among the top collaborators of Alison Pilgrim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison Pilgrim. Alison Pilgrim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 22 | |
| 2 | 76 | |
| 3 | 22 | |
| 4 | Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials breakdown → | 260 |
| 5 | 8 | |
| 6 | 138 | |
| 7 | Iconographies supplémentaires de l'article : Efficacy and tolerability of lasmiditan, an oral 5-HT 1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study | 6 |
| 8 | 124 | |
| 9 | 117 | |
| 10 | 48 | |
| 11 | 69 | |
| 12 | 13 | |
| 13 | 87 | |
| 14 | 150 | |
| 15 | 32 | |
| 16 | 37 | |
| 17 | 5 | |
| 18 | 31 | |
| 19 | 91 | |
| 20 | 17 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.